Hematologia最新文献

筛选

英文中文

Stanowisko polskich ekspertów dotyczące zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chłoniaki skóry CD30+

Hematologia Pub Date : 2018-08-17 DOI: 10.5603/HEM.2018.0015

Małgorzata Sokołowska-Wojdyło, J. Walewski, W. Jędrzejczak, T. Robak, Monika Prochorec-Sobieszek, Joanna Zaucha, Alina Jankowska-Konsur, M. Słowińska, E. Chmielowska, L. Rudnicka, Sebastian Giebel

{"title":"Stanowisko polskich ekspertów dotyczące zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chłoniaki skóry CD30+","authors":"Małgorzata Sokołowska-Wojdyło, J. Walewski, W. Jędrzejczak, T. Robak, Monika Prochorec-Sobieszek, Joanna Zaucha, Alina Jankowska-Konsur, M. Słowińska, E. Chmielowska, L. Rudnicka, Sebastian Giebel","doi":"10.5603/HEM.2018.0015","DOIUrl":"https://doi.org/10.5603/HEM.2018.0015","url":null,"abstract":"The group of primary cutaneous T-cell lymphomas (CTCLs) expressing CD30 + is consisted of primary cutaneous anaplastic T-cell lymphoma (pcACTL), lymphomatoid papulosis (LyP), some cases of mycosis fungoides (MF) and Sezary syndrome (SS). It is well known that patient cannot be cured completely by available therapeutic methods. In addition, the effectiveness of available therapies is especially limited in advanced stages of the disease. Based on the results of the most recent trials, the experts recommend that brentuximab vedotin (BV) should be reimbursed in Poland for the treatment of adult patients with CTCL expressing CD30 who have had at least one prior systemic treatment. In case of MF BV should be preferred to bexarotene or MTX therapy due to the higher efficacy in stage IIB or higher. BV treatment should be also considered as an alternative to bexarotene (after ineffectiveness of local treatment, phototherapy and IFN/MTX therapy) in early stages of MF (IB-IIA).","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"4 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2018-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84710021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Znaczenie oceny minimalnej choroby resztkowej u chorych na przewlekłą białaczkę limfocytową

Hematologia Pub Date : 2018-08-17 DOI: 10.5603/HEM.2018.0013

B. Pula, Adrian Burdacki, M. Dudziński

引用次数: 0

首页上一页